Researchers investigated the effects of SLU-PP-332, a synthetic estrogen-related receptor (ERR) agonist, on metabolic syndrome in an animal model. The compound was found to alleviate metabolic syndrome symptoms, suggesting potential therapeutic applications for this drug target. This is animal model evidence and requires further human clinical investigation before applicability to patient care.
Read more on The Journal of pharmacology and experimental therapeutics →